home / stock / ibrx / ibrx news

IBRX News and Press, ImmunityBio Inc. From 05/18/23

Stock Information
Company Name: ImmunityBio Inc.
Stock Symbol: IBRX
Market: NASDAQ
Website: immunitybio.com
Menu
IBRX IBRX Quote IBRX Short IBRX News IBRX Articles IBRX Message Board
Get IBRX Alerts

News, Short Squeeze, Breakout and More Instantly...
IBRX - Investigation of ImmunityBio, Inc. (IBRX) Announced by Holzer & Holzer, LLC

ATLANTA, May 18, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether ImmunityBio, Inc. (“ImmunityBio,” or the “Company”) (NASDAQ: IBRX) complied with federal securities laws. On May 11, 2023, ImmunityBio disclosed that it received a comple...
IBRX - IBRX INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations Regarding FDA Complete Response Letter

SAN FRANCISCO, May 18, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/IBRX Contact An Attorney Now: IBRX@hbsslaw.com 844-9...

IBRX - ImmunityBio: Amidst Difficulty Is Your Opportunity

2023-05-17 11:23:13 ET Summary Being an extremely volatile stock, ImmunityBio, Inc. is not for all investors. Nevertheless, there are tremendous opportunities in ImmunityBio stock for investors who can stomach higher risks and substantial volatility. Based on the recent Comple...

IBRX - IBRX ALERT: Hagens Berman, National Trial Attorneys, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations Regarding FDA Complete Response Letter

SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2023 / Hagens Berman urges ImmunityBio, Inc. (NASDAQ:IBRX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/IBRX Contact An Attorney Now: IBRX@hbsslaw.com 844-916-0895 ImmunityBi...
IBRX - ImmunityBio: Anktiva Rejection Heightens Financial Urgency

2023-05-12 05:20:49 ET Summary ImmunityBio stock dropped over 50% after the FDA issued a CRL for Anktiva, their lead product for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Despite manufacturing deficiencies, the lack of additional FDA requests for precli...

IBRX - IMMUNITYBIO: Kaplan Fox Investigates ImmunityBio

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Click Here to Join Investigation. ...

IBRX - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations Regarding FDA Complete Response Letter

SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/IBRX Contact An Attorney Now: IBRX@hbsslaw.com 844-9...
IBRX - ImmunityBio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ImmunityBio, Inc. (NASDAQ: IBRX) for potential securities law violations. Investors who have lost money in their ImmunityBio, Inc. investment should contact the firm to learn more about how they might recover those ...

IBRX - Organogenesis, Arcturus top healthcare gainers; ImmunityBio, Dynatronics among losers

2023-05-11 10:00:13 ET Gainers: Organogenesis ( ORGO ) +23% . Arcturus Therapeutics ( ARCT ) +14% . Phathom Pharmaceuticals ( PHAT ) +14% . Pulse Biosciences ( PLSE ) +13% . PharmaCyte Biotech ( PMCB ) +11% . Losers: ImmunityBi...

IBRX - ImmunityBio crashes 57% after FDA snub for cancer therapy

2023-05-11 07:44:31 ET ImmunityBio ( NASDAQ: IBRX ) lost ~57% in the pre-market trading Thursday after disclosing that the FDA rejected a marketing application for its product candidate Anktiva as a combination therapy for a type of bladder cancer. Issuing a so-called comp...
Previous 10 Next 10